{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:00:48Z","timestamp":1791903648734,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"INCa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004097","name":"ARC Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013501","name":"INCA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013501","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009243","name":"DGOS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013501","name":"INCA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013501","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009243","name":"DGOS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013501","name":"INCA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013501","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009243","name":"DGOS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013501","name":"INCA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013501","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Astra-Zeneca"},{"name":"BMS"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"BMS"},{"name":"MSD"},{"DOI":"10.13039\/501100013119","name":"Pharmamar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"name":"BMS"},{"DOI":"10.13039\/100010795","name":"Chugai","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MSD"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GSK"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.annonc.2019.10.022","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T02:40:48Z","timestamp":1578278448000},"page":"289-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"title":["Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations"],"prefix":"10.1016","volume":"31","author":[{"given":"J.","family":"Mazieres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cropet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Montan\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Souquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Quantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dubos-Arvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Favier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Avrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Moro-Sibilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Le Treut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tr\u00e9daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jaffro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Collot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.R.","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tiffon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mahier-Ait Oukhatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2019.10.022_bib1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1634\/theoncologist.2016-0458","article-title":"Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy","volume":"22","author":"Baik","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2019.10.022_bib2","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/JTO.0000000000000644","article-title":"BRAF alterations as therapeutic targets in non-small-cell lung cancer","volume":"10","author":"Nguyen-Ngoc","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2019.10.022_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2019.10.022_bib4","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.annonc.2019.10.022_bib5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.022_bib6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(16)00077-2","article-title":"Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2019.10.022_bib7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2019.10.022_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/annonc\/mdy474","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Planchard","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.022_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2016.31","article-title":"Equal access to innovative therapies and precision cancer care","volume":"13","author":"Buzyn","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.022_bib10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2019.10.022_bib11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/JTO.0000000000000625","article-title":"Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF cohort","volume":"10","author":"Gautschi","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2019.10.022_bib12","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.022_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2018.07.044","article-title":"Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): outcomes with immune check-point inhibitors (ICPi)","volume":"124","author":"Dudnik","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2019.10.022_bib14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jtho.2017.03.005","article-title":"Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling","volume":"12","author":"Schrock","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2019.10.022_bib15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.022_bib16","doi-asserted-by":"crossref","first-page":"60094","DOI":"10.18632\/oncotarget.11635","article-title":"Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of trametinib and dabrafenib","volume":"8","author":"Noeparast","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2019.10.022_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/1078-0432.CCR-18-2062","article-title":"Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer","volume":"25","author":"Dagogo-Jack","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341936079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341936079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:55:38Z","timestamp":1760334938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341936079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S092375341936079X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2019.10.022","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2019.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}